Edwin Kwok

Partner

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

pdf

Edwin Kwok is a partner in O’Melveny’s Hong Kong office. He is a versatile lawyer with extensive experience working with major investment banks, Chinese private companies, Chinese state-owned enterprises, real estate companies and biotech firms on their initial public offerings, cross-border acquisitions, public takeovers, privatizations, spin-offs, and follow-on offerings of equity and debt securities.

Edwin’s extensive experience includes advising on some of the most significant capital markets and mergers and acquisitions transactions in the Asia region.  He has advised on many securities offerings on the Hong Kong Stock Exchange, cross-border mergers and acquisition transactions, and equity-related corporate finance transactions. Recently, he has been advising issuers and underwriters on a number of pre-revenue biotech companies’ listings under the new biotech chapter of the Hong Kong Stock Exchange.

VIEW MORE

Languages

  • English
  • Cantonese
  • Mandarin

Admissions

Bar Admissions

  • Hong Kong
  • England & Wales (non-practising)

Education

  • University of Cambridge, LL.M.
  • University of Hong Kong, LL.B. (First Class Honours), P.C.LL.

ECM Transactions

  • First Shanghai Capital as sole sponsor and First Shanghai Securities as sole global coordinator, and other underwriters in the US$71 Million IPO and listing of Chen Lin Education Group on the Hong Kong Stock Exchange
  • Pharmaron in its approximately US$588 million dual primary listing and H share offering in Hong Kong
  • Fidelity, major shareholder of Innovent Biologics, in Innovent Biologics’ US$412 million IPO on the Main Board of the Hong Kong Stock Exchange
  • Viva Biotech (1873.HK) in its HK$1,521.5 million (approximately US$194 million) IPO and listing on the Hong Kong Stock Exchange
  • Dexin China Holdings Company Limited (2019.HK) in its US$190 million IPO and listing on the Hong Kong Stock Exchange
  • Hua Medicine (2552.HK) in its US$110 million Chapter 18A biotech company IPO sponsored by Goldman Sachs and CLSA Limited
  • China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$133 million IPO of mobile game publisher FingerTango Inc.(6860.HK) on the Hong Kong Stock Exchange
  • China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$40 million IPO of mobile game publisher Digital Hollywood Interactive Limited (2022.HK) on the Hong Kong Stock Exchange
  • Bank of Tianjin in its US$948 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange
  • State-owned shipping giant China Ocean Shipping (Group) Company, and China COSCO Holdings Company Limited and its associated companies in the landmark restructuring involving both China COSCO Group and China Shipping Group, comprising a series of asset acquisitions and disposals among China COSCO, China Shipping and their respective subsidiaries
  • CICC, Goldman Sachs, Morgan Stanley, Citigroup, China Merchants Securities and other underwriters in the US$925 million global offering and listing of H shares of Red Star Macalline Group Corporation Ltd., the largest home improvement and furnishings shopping mall operator in China, on the Main Board of the Hong Kong Stock Exchange
  • BOCOM International, ABCI, Qilu International, and other underwriters in the US$454 million global offering and listing of the H-shares of Guolian Securities Co. Ltd., one of the leading integrated securities firms in China, on the Main Board of the Hong Kong Stock Exchange
  • WH Group, the world’s largest pork company with global leadership across key segments of the industry value chain, including packaged meats, fresh pork, and hog production, in its US$2.36 billion global offering and IPO
  • Haitong International, J.P. Morgan, Credit Suisse, Deutsche Bank, Citigroup and UBS, and other underwriters including HSBC, Nomura, Standard Chartered, and BOCOM International, in the US$1.68 billion H share IPO of Haitong Securities Co. Ltd
  • China Unicom in its US$23 billion merger with China Netcom by way of a scheme of arrangement
  • BOCOM International, Morgan Stanley, Standard Chartered, BOCI Asia, CCB International, and other underwriters in the US$87 million global offering and IPO of New Century Real Estate Investment Trust, the first solely China-based hotel REIT listing in the world
  • J.P. Morgan, as the sole sponsor and financial adviser, in China Daye Non-Ferrous Metals Mining Limited’s deemed new listing and reverse takeover resulting from its RMB5.8 billion acquisition of Prosper Well Group Limited
  • Citigroup, UBS, and CIMB Securities Limited in the US$214 million global offering and IPO of Fu Shou Yuan International Group Limited, one of the largest providers of death care services in the PRC
  • BOCOM International, Macquarie, BOCI Asia, Haitong International, ICBC International, and ABCI in the US$202 million global offering and IPO of Logan Property Holdings Company Limited
  • Morgan Stanley, CITIC Securities Corporate Finance, ICBC International, and other underwriters in the US$130 million global offering and IPO of China VAST Industrial Urban Development Company Limited
  • CICC and GF Securities in the US$172 million global offering and IPO of H shares of China Aluminum International Engineering Corporation Limited
  • Morgan Stanley in the US$180 million global offering of Goodbaby International Holdings Limited
  • CICC, Deutsche Bank AG, Hong Kong Branch, Guotai Junan Securities and CLSA Limited, as the placing agents, in the HK$4.48 billion private H share placement of Sinopec Oilfield Service Corporation (SSC) on the Main Board of the Hong Kong Stock Exchange
  • Macquarie, HSBC and Nomura in the US$200 million global offering and IPO of Top Spring International Holdings, which was the first-ever listing to provide a mixed-media offering in Hong Kong
  • BOCOM International, Haitong International, KGI Capital, and GF Securities in the US$78 million global offering and spin-off listing of China New City Commercial Development Limited from Zhong An Real Estate
  • Goldman Sachs, Morgan Stanley, and HSBC in the spin-off and listing by introduction of Swire Properties
  • Merrill Lynch and Morgan Stanley in the HK$2.56 billion spin-off and global offering of Pou Sheng International (Holdings) Limited
  • Citigroup, JP Morgan, and Rothschild in the global offering and IPO of Trinity Limited
  • ASMC in its HK$700 million H share global offering and IPO sponsored by Goldman Sachs and BOCI
VIEW MORE

Press Releases

O’Melveny Represents BOCOM in Connection With Acquisition of Bonjour Holdings Limited

6月 10, 2020

O’Melveny Represents China Ping An Insurance in US$203 Million Bonds Subscription

5月 8, 2020

O’Melveny Advises China Wan Tong Yuan on its Main Board HKEx Listing

12月 17, 2019

O’Melveny Represents Sponsor and Underwriters in US$71 Million Hong Kong IPO of Chen Lin Education Group

12月 13, 2019

O'Melveny Represents Pharmaron in its US$588 million Hong Kong IPO

11月 28, 2019

O’Melveny Represents Joy Bright in the Unconditional Mandatory General Offer for China Minsheng DIT Group Limited

9月 3, 2019

O’Melveny Represents Joy Bright in Acquisition of US$363 Million of Shares in Central China Real Estate from CapitaLand

7月 18, 2019

O’Melveny Represents China VAST in US$180 Million High Yield Bond Offering

6月 28, 2019

O’Melveny Represents Viva Biotech in its US$194 Million Hong Kong IPO

5月 9, 2019

O’Melveny Represents Property Developer Dexin China in its US$190 Million Hong Kong IPO

2月 26, 2019

O’Melveny Represents Hua Medicine in US$110 Million Hong Kong IPO

9月 14, 2018

O’Melveny Represents Underwriters in US$133 Million Hong Kong IPO of FingerTango

7月 17, 2018

Alerts and Publications